Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of SAR236553 (REGN727) Versus Ezetimibe in Hypercholesterolemia
2011-001424-38Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia (2 arms), sponsored by Sanofi. Started Jun 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2011-001424-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001424-38.